As of Friday, September 18, 2020, 25,976 participants have been enrolled in the Phase 3 COVE study and approximately 28.5% of participants enrolled cumulatively are from diverse communities. 11,879 participants have received their second vaccination. https://t.co/swJNxTd1zg
— Moderna (@moderna_tx) September 19, 2020
Moderna's strategic priorities presented at our 2020 R&D Day event pic.twitter.com/Ik0lMVErcL
— Moderna (@moderna_tx) September 17, 2020
A look at Moderna in September, 2020. #mRNA pic.twitter.com/eElbcvqpIW
— Moderna (@moderna_tx) September 17, 2020
ICYMI: Our collaborations with @VertexPharma to address #cysticfibrosis. Read more: https://t.co/2JTZE4UOwK pic.twitter.com/Mq1UmKW7te
— Moderna (@moderna_tx) September 17, 2020
An independent Data and Safety Monitoring Board (DSMB) ensures continuous data monitoring and enhances participant safety. pic.twitter.com/Z2NRQnCrwp
— Moderna (@moderna_tx) September 17, 2020
Enrollment update for the Phase 3 COVE study of mRNA-1273, our vaccine candidate against COVID-19. #mRNA pic.twitter.com/LwxXqfO5so
— Moderna (@moderna_tx) September 17, 2020
Dr. Jacqueline Miller, Moderna's SVP, Infectious Diseases Development, is now presenting on the clinical development update of our COVID-19 vaccine candidate, mRNA-1273. https://t.co/WiMSqtIn7o pic.twitter.com/JtPc88kp0R
— Moderna (@moderna_tx) September 17, 2020
We remain committed to raising awareness of cytomegalovirus. Learn more here: https://t.co/26gQ72syGa #CMVvoices #StopCMV #CMVawareness #CMVspeaks pic.twitter.com/iwzmWOjYeA
— Moderna (@moderna_tx) September 17, 2020
At R&D Day, Dr. Panther also shared an update on the late stage development plan for our #CMV vaccine candidate, mRNA-1647. Read more here: https://t.co/YqPyTBYId1 pic.twitter.com/qzSBHVsQ6C
— Moderna (@moderna_tx) September 17, 2020
Dr. Lori Panther, Moderna's Senior Director of Clinical Development, Infectious Diseases, is now presenting on the clinical development of our #CMV vaccine candidate, mRNA-1647. #StopCMV #mRNA pic.twitter.com/shdKRlbYf6
— Moderna (@moderna_tx) September 17, 2020
From our R&D Day: An update on our methylmalonic acidemia program, mRNA-3705 https://t.co/p50rA1mpqe #mRNA pic.twitter.com/rJEU08jc79
— Moderna (@moderna_tx) September 17, 2020
To provide additional transparency in context of pandemic, the protocol for the Phase 3 COVE study of mRNA-1273 being conducted in collaboration with the NIH and BARDA is now available: https://t.co/ToJWTwNyYa #mRNA pic.twitter.com/hYaGi1iohK
— Moderna (@moderna_tx) September 17, 2020
We just announced a collaboration with Chiesi Group to discover and develop #mRNA therapeutics for Pulmonary Arterial Hypertension (PAH) read more: https://t.co/R18kmdfqrK pic.twitter.com/x3mIy2a72U
— Moderna (@moderna_tx) September 16, 2020
We are pleased to share that as of today, Friday, September 11th, 23,497
participants have been enrolled in the COVE Phase 3 study of mRNA-1273. Find out more about the trial here: https://t.co/swJNxTd1zg Check back next Friday evening for an updated enrollment number. pic.twitter.com/cQhj3WtRoG— Moderna (@moderna_tx) September 11, 2020
We just announced that we have expanded our footprint in North America with a new Canadian subsidiary and have named Michael Mullette as Managing Director, Canada. Read more: https://t.co/IPhl0dYNDw pic.twitter.com/ivY7v6uWwH
— Moderna (@moderna_tx) September 10, 2020
We are proud to participate in this pledge to uphold the integrity of the scientific process in the research and development of a #COVID19 vaccine. #WeStandWithScience, and @BioNTech_Group, we invite you to stand with us. https://t.co/O1wDca3KoU pic.twitter.com/34Y2VMRTrS
— Moderna (@moderna_tx) September 8, 2020
Just announced: Biopharma leaders unite to stand with science https://t.co/OFK5jgLyAa #westandwithscience pic.twitter.com/r9O1ahEZ10
— Moderna (@moderna_tx) September 8, 2020
Moderna Confirms Discussions with the Ministry of Health, Labour and Welfare to Supply Japan with 40 Million Doses of mRNA Vaccine Against COVID-19 (mRNA-1273): https://t.co/jpsGTOv9BQ pic.twitter.com/fo0XC7pCXo
— Moderna (@moderna_tx) August 28, 2020
Dr. Jacqueline Miller, our Sr. Vice President of Infectious Disease Development is now presenting at the ACIP meeting. View slides here: https://t.co/MWMns8FCdW and watch the presentation here: https://t.co/u8xGxAWtlE pic.twitter.com/IopB2kVAN7
— Moderna (@moderna_tx) August 26, 2020
Moderna is presenting at the @CDCgov Advisory Committee on Immunization Practices (ACIP) August Meeting today. Read more here: https://t.co/uUJ7W3sNLU pic.twitter.com/qS9MMt4vSY
— Moderna (@moderna_tx) August 26, 2020
We just announced that we have concluded advanced exploratory talks with the European Commission to supply 80 million doses of mRNA-1273. Read more here: https://t.co/mRNWi2ffPh pic.twitter.com/Q83RYHphmH
— Moderna (@moderna_tx) August 24, 2020
Our commitment to #diversity and #inclusion pic.twitter.com/zWURhsLD6i
— Moderna (@moderna_tx) August 21, 2020
We just announced a supply agreement with the U.S. government for an initial 100 million doses of mRNA-1273, our vaccine candidate against COVID-19. Read more here: https://t.co/skd7iLdEW2 pic.twitter.com/JwZ7OD7EjO
— Moderna (@moderna_tx) August 11, 2020
Tune in to this new podcast to hear Dr. Tal Zaks, our Chief Medical Officer discuss the importance of #diversity and #inclusion in #clinicaltrials with @IAmBiotech CEO @DrMichelleBIO . Stream on your favorite podcast platform or click here: https://t.co/Qe11EERCGB pic.twitter.com/0zYSIg6hnw
— Moderna (@moderna_tx) August 7, 2020
A snapshot of Moderna in August, 2020 pic.twitter.com/HMWdg8DNcW
— Moderna (@moderna_tx) August 5, 2020
“As we pivot to a commercial stage company, we recognize the need for responsible pricing in the face of the pandemic.” – Stéphane Bancel, Moderna’s CEO pic.twitter.com/mOQHF2QNYc
— Moderna (@moderna_tx) August 5, 2020
Data generated to date for mRNA-1273, our vaccine candidate against COVID-19 include: pic.twitter.com/9MwtwZon2H
— Moderna (@moderna_tx) August 5, 2020
Our Chief Medical Officer Dr. Tal Zaks details the late stage development for our #CMV #vaccine candidate (mRNA-1647). #StopCMV pic.twitter.com/OE5x6FRUm0
— Moderna (@moderna_tx) August 5, 2020
Our CEO, Stéphane Bancel highlights accomplishments from the second quarter 2020. Read more: https://t.co/gn25wTczlp $MRNA pic.twitter.com/xP0NFSpWLE
— Moderna (@moderna_tx) August 5, 2020
Just published in @nature : SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness. Read the manuscript here: https://t.co/v07pB2RzXH pic.twitter.com/MKq0Stux14
— Moderna (@moderna_tx) August 5, 2020
We just announced the publication of a nonhuman primate preclinical viral challenge study of mRNA-1273 in @NEJM. Read more: https://t.co/5xE2gjC05P pic.twitter.com/1rjK7gELnO
— Moderna (@moderna_tx) July 28, 2020
Just published in @NEJM : Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates. Read the manuscript here: https://t.co/wCfuu7z1WI
— Moderna (@moderna_tx) July 28, 2020
We just announced that the Phase 3 study of mRNA-1273, our vaccine candidate against COVID-19 has begun. The Phase 3 study being conducted in collaboration with @NIH and @BARDA. Read more here: https://t.co/Xi9SV6fk4z pic.twitter.com/oESeuKjF08
— Moderna (@moderna_tx) July 27, 2020
We just announced an expansion of our agreement with @BARDA for up to an additional $472 million to support our late stage clinical development of mRNA-1273, including the execution of a 30,000 participant Phase 3 study in the U.S. Read more: https://t.co/g9r7aXtguI pic.twitter.com/5bhmfEkQ5t
— Moderna (@moderna_tx) July 26, 2020
We just announced interim results from the NIH-led Phase 1 Study of our #mRNA #vaccine against COVID-19 (mRNA-1273) in @NEJM. Read more: https://t.co/YqPyTCgjBB pic.twitter.com/e2AStO92ES
— Moderna (@moderna_tx) July 14, 2020
Moderna to join the #NASDAQ100 Index beginning July 20, 2020: https://t.co/21Co0CYOhr $MRNA @Nasdaq pic.twitter.com/wZnKin0GDx
— Moderna (@moderna_tx) July 14, 2020
The https://t.co/XvCSRI7uD8 listing for Moderna’s Phase 3 study of mRNA-1273, our #vaccine candidate against COVID-19 is now live. Find more information on the study including site locations here: https://t.co/9uIYZ069JU pic.twitter.com/QkPEoAXw7b
— Moderna (@moderna_tx) July 14, 2020
We just announced a collaboration with @Rovi_IR for OUS fill-finish manufacturing of our COVID-19 #vaccine candidate. Read more here: https://t.co/3EdEYj80xZ #mRNA pic.twitter.com/iJMZxJTi2B
— Moderna (@moderna_tx) July 9, 2020
We have completed enrollment of our Phase 2 study of mRNA-1273, our vaccine candidate against COVID-19. Read this morning's press release here: https://t.co/RZWlyCgUUd pic.twitter.com/FBMsaH20Pg
— Moderna (@moderna_tx) July 8, 2020
We just announced that Elizabeth Tallett has joined our Board of Directors. Read more: https://t.co/TSSrenSziD pic.twitter.com/2yfK1aUKnC
— Moderna (@moderna_tx) July 1, 2020
CMV Parent, Farah sits down with Moderna's Drew Nathenshon to honor & remember her daughter Maddie who passed away due to complications associated with CMV 12 days after her birth. Watch our new #CMVvoices video here: https://t.co/lWMBCe7VGe #StopCMV pic.twitter.com/NvxVeUwRs1
— Moderna (@moderna_tx) June 29, 2020
We just announced a collaboration with @CatalentPharma for fill-finish manufacturing of mRNA-1273, our COVID-19 #vaccine candidate. Read more https://t.co/8Uldz2BwuI pic.twitter.com/81Px3RW69Q
— Moderna (@moderna_tx) June 25, 2020
We are delighted to share that Ray Jordan has joined Moderna as Chief Corporate Affairs Officer, effective today. Read more: https://t.co/HnrdAcFQfa pic.twitter.com/HXovsuN7RF
— Moderna (@moderna_tx) June 15, 2020
We are pleased to share a preprint of the preclinical manuscript for our #vaccine against #SARS-CoV-2 to potentially prevent #COVID19 disease. We thank the NIAID team for their collaboration with our infectious disease research team. https://t.co/weLnGLvfv3 @NIAIDNews
— Moderna (@moderna_tx) June 12, 2020
We just announced an update on late-stage development of our vaccine (mRNA-1273) against COVID-19. Read more: https://t.co/eVwiVzaz5L pic.twitter.com/EyoOYGRFky
— Moderna (@moderna_tx) June 11, 2020
We are delighted to announce that David Meline has joined Moderna as Chief Financial Officer, effective Monday, June 8, 2020. Read more: https://t.co/U77O8Iikij $MRNA pic.twitter.com/FHRCeErUif
— Moderna (@moderna_tx) June 4, 2020
Today, at our third annual Science Day, we are highlighting our #mRNA platform science and innovative vaccine research. Read more & join the webcast beginning at 8am ET: https://t.co/gtlL0F0A4D pic.twitter.com/tnlmmHSvbp
— Moderna (@moderna_tx) June 2, 2020
We just announced that the first participants in each age cohort have been dosed in the Phase 2 study of our mRNA vaccine (mRNA-1273) against novel coronavirus. Read more: https://t.co/woPlKz1bZC #mRNA pic.twitter.com/9VGUoJu5cS
— Moderna (@moderna_tx) May 29, 2020
During a @CNN interview yesterday, Dr. Anthony Fauci explained why he is encouraged by early findings in the NIH-led Phase 1 study of mRNA-1273. https://t.co/eIMGBSnhsQ pic.twitter.com/j3gczwYL24
— Moderna (@moderna_tx) May 22, 2020
In our call with Governors today, Dr. Fauci shared exciting news from biotech company, Moderna! The first potential Coronavirus vaccine has shown promising results in a clinical trial. 45 participants received 2 doses of the vaccine & all 45 produced antibodies.
— Mike Pence (@Mike_Pence) May 19, 2020
Summary of our SARS-CoV-2 #vaccine (mRNA-1273) interim Phase 1 data. Read more: https://t.co/aIq34ullAh #mRNA pic.twitter.com/BVbYuWTkOy
— Moderna (@moderna_tx) May 18, 2020
Our #CMV Phase 2 dose confirmation study is fully enrolled & the first Phase 2 interim analysis is expected in the third quarter of 2020. #mRNA #StopCMV https://t.co/5XdkPGIpUw pic.twitter.com/4EHG6atobG
— Moderna (@moderna_tx) May 7, 2020
Moderna and @LonzaPB announce worldwide strategic collaboration to manufacture Moderna's #vaccine (mRNA-1273) against novel coronavirus. Read more: https://t.co/sz7RYbLFmH #mRNA pic.twitter.com/2C3NIBM9oV
— Moderna (@moderna_tx) May 1, 2020
We just announced that we have submitted an IND application to the U.S. FDA for a Phase 2 study of our mRNA Vaccine (mRNA-1273) against novel coronavirus. Read more: https://t.co/5w6UcdHc2Y pic.twitter.com/eKnA1DDYZ9
— Moderna (@moderna_tx) April 27, 2020
At Moderna, we strive to pursue innovative ways to grow our business while minimizing our environmental footprint. Read about our efforts to manage our environmental impact in our corporate social responsibility framework: https://t.co/u1858CDFzc #EarthDay pic.twitter.com/aBtl84mLJJ
— Moderna (@moderna_tx) April 22, 2020
We just announced an award from U.S. government agency @BARDA for up to $483 million to accelerate development of our mRNA vaccine (mRNA-1273) against novel coronavirus https://t.co/Sn20aJVr8Z pic.twitter.com/DbvywrTPcB
— Moderna (@moderna_tx) April 16, 2020
Moderna's #mRNA vaccine candidate against the novel coronavirus: from concept to Phase 1 in 42 days pic.twitter.com/rGyfyRzSlv
— Moderna (@moderna_tx) April 14, 2020
The NIH-led Phase 1 study of mRNA-1273, Moderna’s vaccine candidate against the novel coronavirus, continues on track with enrollment of participants at the highest dose pic.twitter.com/RhvsmBlvt3
— Moderna (@moderna_tx) April 14, 2020
#CMV is the most common infectious cause of birth defects in the U.S.; there is no approved #vaccine to prevent CMV. mRNA-1647 is Moderna's #mRNA vaccine candidate against CMV. #stopCMV pic.twitter.com/52vE1XImVG
— Moderna (@moderna_tx) April 14, 2020
1st interim analysis of Phase 1 Zika vaccine candidate (mRNA-1893) study shows that 10 µg & 30 µg dose levels seroconverted 94% & 100% of seronegative participants, respectively, and effectively boosted seropositive participants. Both dose levels were generally well-tolerated. pic.twitter.com/3hJrNjhaee
— Moderna (@moderna_tx) April 14, 2020
An analysis by @AndrewWLo compared #infectiousdisease vaccines to other therapeutic areas & found that #vaccines have an overall 33% probability of success that increases to 42% once a Phase 2 study is launched, the highest of all therapeutic areas. https://t.co/4T9DzZKzBS pic.twitter.com/5CCbc1LDwE
— Moderna (@moderna_tx) April 14, 2020
Accelerated research and development timelines are a potential advantage of #mRNA vaccines pic.twitter.com/s51Ex9k6dJ
— Moderna (@moderna_tx) April 14, 2020
Vaccines create significant value for healthcare systems by preventing infectious disease; despite this, the vast majority of viruses do not have commercial vaccines available, representing a large opportunity pic.twitter.com/lflRFYu73z
— Moderna (@moderna_tx) April 14, 2020
We just announced that we will highlight the potential opportunities of mRNA vaccines at our first Vaccines Day. Read more: https://t.co/ttEhFhlY2h pic.twitter.com/LJ4nw7onYk
— Moderna (@moderna_tx) April 14, 2020
Congratulations to Said Francis, SVP, head of business development & corporate strategy at Moderna, for being named one of @Endpoints #20under40 ! https://t.co/hRBQaiSrf8
— Moderna (@moderna_tx) April 6, 2020
Our CEO Stéphane Bancel participated in a webinar with @AndrewWLo to discuss Moderna’s work on our vaccine candidate against the novel coronavirus. Tune in here: https://t.co/QZqmPqhyCO
— Moderna (@moderna_tx) April 3, 2020
Today, we took steps to speed the development and secure domestic manufacturing of two vaccines – one by @Moderna_tx & another by @JanssenUS – to prevent the spread of #COVID19 and protect people at home and abroad. https://t.co/2X5aBSkbKY pic.twitter.com/tr4oSv6Qm7
— BARDA (@BARDA) March 30, 2020
Tune in to hear Moderna CEO Stéphane Bancel & @JimGreenwood of @IAmBiotech discuss our vaccine candidate (mRNA-1273) against COVID-19. Moderna delivered the vaccine candidate to the @NIH for their Phase 1 study in 42 days from sequence selection. https://t.co/MoLpWJ7sbj #mRNA pic.twitter.com/vxCMPRMLzM
— Moderna (@moderna_tx) March 30, 2020
.@EmoryUniversity in Atlanta will begin enrolling participants in the NIH-led Phase 1 clinical trial of mRNA-1273, Moderna’s vaccine against COVID-19 #mrna https://t.co/y0z1xCHBsR
— Moderna (@moderna_tx) March 27, 2020
We just announced that the first participant has been dosed in the NIH-led Phase 1 study of our #mRNA vaccine (mRNA-1273) against novel coronavirus https://t.co/14SDfdI1Az pic.twitter.com/LnJWYhAbkx
— Moderna (@moderna_tx) March 16, 2020